Lakefront Biotherapeutics NV ADR(LKFT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 7:30 PM ET (Korea 9/26 08:30)
Full metrics table
| Index | - | P/E | 2.79 | EPS (ttm) | 10.52 | Insider Own | 25.35% | Shs Outstand | 65.7M | Perf Week | 2.91% |
| Market Cap | 1.93B | Forward P/E | - | EPS next Y | 4.98% | Insider Trans | - | Shs Float | 49.0M | Perf Month | 0.75% |
| Enterprise Value | -0.62B | PEG | - | EPS next Q | -0.83 | Inst Own | 23.39% | Short Float | 6.96% | Perf Quarter | -0.34% |
| Income | 0.69B | P/S | 1.67 | EPS this Y | -144.34% | Inst Trans | 1.96% | Short Ratio | 13.89 | Perf Half Y | -1.97% |
| Sales | 1.15B | P/B | 0.52 | EPS next 5Y | - | ROA | 16.62% | Short Interest | 3.41M | Perf YTD | -10.15% |
| Book/sh | 56.83 | P/C | 0.75 | EPS past 3/5Y | - | ROE | 20.22% | 52W High | -22.23% ($37.78) | Perf Year | -10.04% |
| Cash/sh | 39 | P/FCF | - | Sales past 3/5Y | 70.43% 18.16% | ROIC | 18.56% | 52W Low | 14.41% ($25.68) | Perf 3Y | -15.36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 323.94% | Gross Margin | 97.45% | Volatility(W/M) | 3.57% 2.55% | Perf 5Y | -45.03% |
| Dividend TTM | - | EV/Sales | -0.54 | Sales Y/Y TTM | 285.48% | Oper. Margin | 59.54% | ATR (14) | 0.9 | Perf 10Y | -58.62% |
| Dividend Ex-Date | - | Quick Ratio | 32.7 | EPS Q/Q | 101.92% | Profit Margin | 60.14% | RSI (14) | 54.49 | Recom | 2.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 32.82 | Sales Q/Q | -80.97% | SMA20 | 2.95% ($28.54) | Beta | 0.24 | Target Price | $34.02 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/10 | SMA50 | 3.93% ($28.27) | Rel Volume | 1.02 | Prev Close | $30.36 |
| Employees | 452 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 114.61% 32.08% | SMA200 | -2.72% ($30.2) | Avg Volume(3M) | 0.25M | Price | $29.38 |
| IPO | 2008/7/7 | Option/Short | Yes/Yes | Trades | 2977 | Volume | 250,702 | Change | -3.23% |
🧬 A European-based clinical-stage biotech company developing therapeutics for cancer and immune diseases. It develops drug candidates targeting hematologic cancers and autoimmune diseases through differentiated approaches such as cell therapy and immune modulation, and is expanding its pipeline through collaborations with major pharmaceutical companies. This is a clinical-stage biotech that changed its name from the former Galapagos, focusing on the immuno-oncology and autoimmune disease sectors.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
Traded about as much as usual That is 102% of its average volume.
LKFT makes money exceptionally well
Of every $100 in sales, $59.54 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -144.3% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $279. Peers typically go for $991.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -45.0%. The S&P 500 did +74% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 23.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #110 of 593 in the industry
Based on market cap of $2B.
FAQ
What kind of company is LKFT?
LKFT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LKFT?
The market cap of LKFT is approximately $1.9B, ranking 2,112 within its sector.
What is the P/E ratio of LKFT?
LKFT has a P/E ratio of approximately 2.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LKFT?
LKFT has recorded a 52-week high of $37.78 and a low of $25.68.
